IPP Bureau
Nihilent launches nSEPIA Beta, introduces AI-driven emotional wellness platform
By IPP Bureau - April 25, 2026
AI-powered platform uses real-time emotion scanning and personalised interventions to make emotional wellness measurable and actionable
India Autism Center hosts ‘Sports for All’ initiative to advance inclusive sporting ecosystem
By IPP Bureau - April 25, 2026
Multi-stakeholder initiative highlights inclusive sports pathways, honours neurodivergent athletes, and calls for systemic reforms
Azelis posts resilient Q1 as acquisitions mask organic slowdown and cash flow strengthens
By IPP Bureau - April 25, 2026
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
Bayer’s comeback gains speed as CEO warns: “The Work Isn’t Complete. Yet"
By IPP Bureau - April 25, 2026
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Siegfried locks in major CDMO expansion deal as US & Australia sites join global network from May 1
By IPP Bureau - April 25, 2026
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Takara Bio, Resistomap join forces to streamline AMR surveillance from environmental samples
By IPP Bureau - April 24, 2026
Collaboration integrates SmartChip PCR technology with cloud-based analytics to enable faster, standardised monitoring of antimicrobial resistance
New genomics clinic by Fortis Hospitals targets early disease detection
By IPP Bureau - April 24, 2026
New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care
Rossari Biotech reviews capex, delays Unitop and Tristar expansion rollout
By IPP Bureau - April 24, 2026
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
Sai Life Sciences allots 2.44 lakh equity shares under employee stock option schemes
By IPP Bureau - April 24, 2026
Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms
Clariant boosts high-speed packaging efficiency with expanded continuous strip desiccant reels
By IPP Bureau - April 24, 2026
Extending production capabilities to the Americas helps reduce labor costs and inventory complexity for nutraceuticals and other industries while maintaining superior moisture control
Novo Nordisk posts strong late-stage results for oral diabetes pill in children and teens
By IPP Bureau - April 24, 2026
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Biocon receives Health Canada approval for Bosaya and Vevzuo biosimilars to Prolia and Xgeva
By IPP Bureau - April 24, 2026
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Shilpa Medicare appoints Dr Vellaian Karuppiah as COO – Formulations
By IPP Bureau - April 24, 2026
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
K J Somaiya Hospital upgrades diagnostics with 1.5T MRI, NICU ventilators under Kotak Mahindra Bank CSR support
By IPP Bureau - April 24, 2026
The transition from an outsourced MRI model to an in-house facility marks more than an infrastructure upgrade
Gujarat Themis Biosyn to acquire anti-TB and anti-infective brands from Sanofi for EUR 158 Million
By IPP Bureau - April 24, 2026
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
